Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.
Given that T1D patients share many of the same comorbidities as T2D patients, doctors have been prescribing them to T1D patients ‘off label’.
For over 12 years, dQ&A has gathered primary data from diabetes healthcare practitioners (HCPs)—notably endocrinologists and primary care physicians—expanding our ‘Prescriber Perspectives’ tracker to five countries with insights from key prescribers and influencers.
